Asterias biotherapeutics, inc. (AST)
Income statement / Yearly
Dec'17Dec'16Dec'15Dec'14Dec'13Sep'13
us-gaap_GrantMember
License Revenue [Member]
Royalties from Product Sales [Member]
REVENUE
Grant income

3,711

6,572

3,007

1,035

0

-

Sale of cell lines

0

0

40

0

0

-

License revenue

0

125

0

0

-

-

Royalties from product sales

331

257

535

189

0

-

Total revenues

4,042

6,954

3,582

1,224

0

-

Cost of sales

165

128

268

95

0

-

Gross profit

3,877

6,826

3,314

1,129

0

-

EXPENSES
Research and development

26,640

25,467

17,321

13,310

4,319

1,931

Acquired in-process research and development

-

-

-

-

17,459

-

General and administrative

10,488

15,482

7,901

5,280

3,883

3,646

Total operating expenses

37,128

40,949

25,222

18,590

25,661

5,577

Loss from operations

-33,251

-34,123

-21,908

-17,461

-25,661

-5,577

OTHER INCOME/(EXPENSE)
Gain from change in fair value on warrant liability

5,908

-3,108

0

0

-

-

Interest expense, net

-465

-546

-341

-10

-

-

Interest expense, net

-

-

-

-

-2

-

Other expense, net

-564

-37

-6

-2

2

-

Gain on sale of fixed assets

-

-

-

-

-

2

Other income/(expense), net

-

-

-

-

-

1

Total other income/(expense), net

4,879

-3,691

-347

-12

0

4

LOSS BEFORE INCOME TAX BENEFIT

-28,372

-37,814

-22,255

-17,473

-25,661

-

Deferred income tax benefit

0

-2,325

-7,252

-7,376

-3,281

-

NET LOSS

-28,372

-35,489

-15,003

-10,097

-22,380

-

NET LOSS

-

-

-

-

-

-5,573

BASIC AND DILUTED NET LOSS PER SHARE (in dollars per share)

-0.56

-0.83

-0.42

-0.33

-2.90

-107.84

WEIGHTED AVERAGE SHARES OUTSTANDING: BASIC AND DILUTED (in shares)

50,271

42,934

35,443

30,720

7,726

51